Analyst Group Comment on Eevia Health’s Divestment of the Eye-Health Candidate Retinari

On February 4thth, Eevia Health Plc (publ) (“Eevia”) announced that the Company has agreed to sell IP related to the leading eye-health compound, Retinari™, to Havu Health Oy for EUR 800k, equivalent to approx. SEK 9.2m. Retinari™ is a promising compound in fighting Age-related Macular Degeneration (AMD), the primary cause of blindness.